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Abstract The aim of this pilot study was to evaluate the use
of PET/CT with
18F-fluorocholine in the differentiation of
hepatocellular adenoma (HCA) from focal nodular hyper-
plasia (FNH). Patients with liver lesions larger than 2 cm
suspicious for HCA or FNH were prospectively included.
All patients underwent PET/CT with
18F-fluorocholine and
histopathological diagnosis was obtained by either liver
biopsy or surgery. The ratios between the maximum
standardized uptake value (SUV) of the lesion and the mean
SUV of normal liver parenchyma were calculated and a
receiver operating characteristic (ROC) curve analysis was
performed. Ten patients with FNH and 11 with HCA were
included. The mean SUV ratio was 1.68±0.29 (±SD) for
FNH and 0.88±0.18 for HCA (p<0.001). An SUV ratio cut-
off value between 1.12 and 1.22 differentiated patients with
FNH from those with HCAwith 100% sensitivity and 100%
specificity. This pilot study showed that PET/CT with
18F-
fluorocholine can differentiate HCA from FNH.
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Abbreviations
PET Positron emission tomography
CT Computed tomography
FNH Focal nodular hyperplasia
HCA Hepatocellular adenoma
SUV Standardized uptake value
ROC Receiver operating characteristics
Introduction
Hepatocellular adenoma (HCA) and focal nodular hyper-
plasia (FNH) are benign hypervascular liver lesions that
predominantly occur in young and middle-aged women.
Differentiation of these two tumours using radiological
imaging modalities may be difficult because of radiological
features shared by both tumours [1]. The frequency with
which the diagnosis is in question after routine radiological
examination is unclear. Recently it has been reported that
MRI with a hepatospecific contrast agent distinguishes
HCA from FNH with a sensitivity and specificity of 96.9%
and 100%, respectively. However, the diagnosis of most of
these lesions was based solely on imaging results without
histological confirmation [2]. Differentiation is crucial to
decide on appropriate management because of the different
therapeutic consequences. FNH is a strictly benign liver
lesion and complications are very rare. Conservative
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DOI 10.1007/s00259-010-1584-0treatment is therefore justified, in the absence of mechan-
ical symptoms. On the other hand, HCA carries a risk of
spontaneous bleeding [3] and malignant transformation,
especially when the lesion is larger than 5 cm [4].
Therefore, resection of a HCA larger than 5 cm is usually
advocated.
When radiological analysis remains inconclusive, a liver
biopsy is required to establish the diagnosis. This is an
invasive procedure with associated risks. Therefore, there is
a need for accurate noninvasive diagnostic imaging
techniques. In previous studies, the use of the
99Tc
sulphur-colloid scan was found not to be helpful in
diagnosis because many lesions showed atypical uptake of
the tracer [5]. In our experience, the use of
99Tc mebrofenin
is not accurate enough, probably due to inferior resolution
of SPECT or biliary excretion on hepatobiliary scintigraphy
masking smaller centrally located lesions. Bumsel and et al.
recently suggested that PET/CT using the tracer
18F-
fluoromethylcholine (
18F-FCH) may be able to differentiate
between FNH and HCA [6]. In this pilot study, we
prospectively assessed the use of PET/CT with
18F-FCH
with semiquantitative uptake measurements in patients in
whom the diagnosis FNH or HCA was considered.
Materials and methods
Patients
This pilot study was part of a prospective, single-centre trial
which aimed to develop a diagnostic algorithm for patients
with suspicion of FNH or HCA. The study protocol was
approved by the medical ethics committee of the Academic
Medical Center Amsterdam. Patients over 18 years of age
with suspicion of FNH or HCA larger than 2 cm in diameter
basedonradiologicalimaging modalitieswereincludedinthe
studyafterwritteninformedconsenthadbeenobtained.When
suspected of malignancy, based on clinical history, imaging
studies or elevated plasma alpha-fetoprotein or CEA levels,
the patient was excluded.
PET/CT procedure
An injection solution of 2,000–3,000 MBq of [
18F]-
fluorocholine with a radiochemical purity of 98% or more
was synthesized. PET/CT was performed using a Philips
Gemini TF-16 PET/CT scanner (Philips Medical Systems,
Eindhoven, The Netherlands) with a spatial resolution near
Table 1 Patient characteristics and PET/CT data
Patient Gender Age
(years)
Tumour location
(segment)
Tumour
size (cm)
SUVmean
liver
SUVmax
tumour
SUV
ratio
Histopathological
diagnosis
Treatment
1 F 29 2 5.3×4.2 10.61 6.03 0.57 HCA Segmental resection
2 F 45 7 5.0×6.0 8.77 5.49 0.63 HCA Segmental resection
3 F 33 8 5.5×4.5 12.87 8.66 0.67 HCA Right hemihepatectomy
4 F 35 2 6.0×7.5 8.86 7.57 0.85 HCA Segmental resection
5 F 49 8 7.0×5.9 10.56 9.24 0.88 HCA Right hemihepatectomy
6 F 40 3 2.3×1.9 12.47 11.52 0.92 HCA Observation
7 F 41 7 2.3×1.4 8.45 7.93 0.94 HCA Observation
8 F 51 8 8.5×6.5 10.95 10.55 0.96 HCA Right hemihepatectomy
9 F 45 3 6.0×7.0 9.36 9.27 0.99 HCA Observation
10 F 41 6 8.0×4.0 11.91 12.96 1.09 HCA Segmental resection
11 F 40 1 11.4×9.3 11.48 12.90 1.12 HCA Enucleation of the tumour
12 F 27 4 4.2×4.5 16.09 19.62 1.22 FNH Observation
13 F 38 1 5.7×6.8 7.21 10.16 1.41 FNH Enucleation of the tumour
14 F 38 4 2.4×2.2 7.08 10.29 1.45 FNH Enucleation of the tumour
15 F 22 8 6.2×5.0 6.70 10.51 1.57 FNH Right hemihepatectomy
16 F 41 5 7.8×7.2 10.68 17.25 1.62 FNH Observation
17 F 52 7 6.4×6.3 8.89 15.15 1.70 FNH Observation
18 F 44 5 3.1×2.7 10.00 18.38 1.84 FNH Observation
19 F 45 8 7.1×7.4 6.82 12.76 1.87 FNH Observation
20 F 40 2 3.7×3.1 8.43 16.29 1.93 FNH Enucleation of the tumour
21 F 36 7/8 10.5×6.3 9.24 20.39 2.21 FNH Observation
Eur J Nucl Med Mol Imaging (2011) 38:436–440 437the centre of the field of view of 4.8 mm in transverse and
axial directions. A CT transmission scan in the supine
position was acquired from the mid-thorax to the mid-
abdomen, encompassing the entire liver. The 12-channel
helical CT scanning parameters were: 120 kVp, 50 mA/
slice, rotation time 0.75 s, slice thickness/interval 5.0 mm.
No intravenous contrast agent was used for the CT. At
15 min after intravenous injection of 150 MBq of
18F-
FCH, emission scans were acquired from the mid-thorax
to the mid-abdomen, encompassing the entire liver over
three or four bed positions at 3 min per position. Images
were reconstructed using a list-mode version of a
maximum likelihood expectation maximization algorithm
with a time-of-flight kernel applied in both the forward
and back-projection operations. CT data were used for
attenuation correction.
PET/CT evaluation
Images were analysed in consensus blinded for outcome
on a Hermes workstation using Hybrid viewer software
(Hermes Medical Solutions,S t o c k h o l m ,S w e d e n ) .T h e
standardized uptake value (SUV) was determined in the
liver lesions and in surrounding nonaffected liver tissue
volumes. Choline is normally continuously metabolized
in the liver. The amount of choline used depends on the
metabolic need, and therefore is not necessarily equal
between patients. To allow for this different baseline
choline consumption, we used the SUV ratio in our
analysis. The SUV ratio was calculated by dividing the
maximum SUV of the lesion (SUVmax tumour) by the
mean SUV of the normal surrounding liver tissue
(SUVmean liver).
Fig. 1 CT and PET/CT images
of a patient with FNH (a) and
HCA (b) 15 min after i.v.
injection of 150 MBq
18F-FCH.
The FNH clearly shows in-
creased uptake of the choline
tracer. The HCA is hardly dis-
tinguishable from, but relatively
cold compared to normal liver
tissue
Fig. 2 Boxplot differentiating FNH and HCA in terms of choline
metabolic activity of the tumour. The cut-off value of the SUV ratio
with 100% sensitivity and 100% specificity lies between 1.12 to 1.22
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The gold standard for the diagnosis of FNH and HCA is
histopathological evaluation. A histological specimen was
obtained by liver biopsy or liver surgery. If multiple lesions
were present in the liver, only those with a histopatholog-
ically confirmed diagnosis were scored using the PET/CT
scan. The outcome of the PET/CT scan was compared with
the gold standard.
Statistical analysis
Statistical analysis was performed with Statistical Package
for Social Sciences (SPSS, version 16.0.2.1). Continuous
data were tested for normality of distribution and equality
of variances using Levene’s test, and compared using an
independent sample t-test, and are expressed as means ±SD.
All statistical tests were two-tailed, and were evaluated at
the 5% level of significance. A receiver operating charac-
teristic (ROC) curve analysis was performed.
Results
Patient characteristics
Included in the study were 21 patients in the period
between May 2009 and January 2010. All patients were
female and their mean age was 39 years (range 22–
52 years). Patient characteristics are shown in Table 1.
PET/CT performance
Ten patients had histologically proven FNH and 11 had
HCA. There were no complications after the liver biopsies.
The mean SUV ratios were 1.68±0.29 (range 1.22–2.21) for
FNH and 0.88±0.18 (range 0.57–1.12) for HCA (p<0.001).
All FNH therefore showed increased uptake and most
HCAs showed similar or decreased uptake of the choline
tracer in comparison to the surrounding liver tissue (Fig. 1).
ROC curve analysis suggested that a SUV ratio cut-off
value between 1.12 and 1.22 differentiated patients with
FNH from those with HCA with 100% sensitivity and
100% specificity. The SUV ratios for each group are shown
in Fig. 2.
Discussion
This study shows that PET/CT with
18F-FCH can differen-
tiate FNH from HCA. All HCAs showed an SUV ratio
≤1.12 and all FNH showed an SUV ratio ≥1.22. The 100%
sensitivity and specificity based on visual interpretation are
in accordance with the findings of Bumsel et al. [6]. They
found an intense and early uptake of FCH by all FNH and
no uptake by adenoma or telangiectatic FNH. The latter
lesion has, however, recently been reclassified as HCA [7].
The results of both studies are promising, but must be
considered carefully because of the small sample size. In
our ongoing study we will further assess the accuracy of
PET/CT with
18F-FCH in more patients.
Thequestionarisesastothephenomenonthatunderliesthe
difference in choline uptake. Choline is used in the synthesis
of phosphatidylcholine and sphingomyelin, two phospholi-
pids that are structural components of all human cell
membranes. Malignant tumour cells are known to show rapid
cell duplication and therefore have a higher uptake of choline
as a substrate for the cell membranes. However, HCA and
especially FNH are slowly proliferating liver tumours making
thisduplicationtheoryunlikely. Anothertheoryisa difference
in perfusion, since choline uptake is flow-dependent [8]. On
hepatobiliary scintigraphy, FNH shows increased flow, in
contrast to HCA. On contrast-enhanced ultrasonography,
both FNH and HCA show rapid filling of the lesion, but an
HCA also shows rapid wash-out of the contrast material [9].
Finally, there could be a difference in the metabolism of very
low-density lipoproteins (VLDL) in the tumours. The
membrane of VLDL particles mainly consists of phospho-
lipids. Although less plausible, it could be that FNH has an
increased synthesis of VLDL particles.
A drawback of the use of PET/CT using noncontrast-
enhanced low-dose CT is that the tumours might be difficult
to localize. In such cases image fusion with a contrast-
enhanced CT or MRI scan is needed to locate the lesions.
Based on the findings of this study, we can conclude that
PET/CT with
18F-fluorocholine is able to differentiate HCA
from FNH with high sensitivity and specificity. Study of a
larger patient series is, however, needed to confirm these
results.
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